المؤلفون: Molino, Silvia, Pisarevsky, Andrea, Badu, Shyam, Wu, Qinglong, Mingorance, Fabiana López, Vega, Patricia, Stefanolo, Juan Pablo, Repetti, Julieta, Ludueña, Guillermina, Pepa, Pablo, Olmos, Juan Ignacio, Fermepin, Marcelo Rodriguez, Uehara, Tatiana, Viciani, Elisa, Castagnetti, Andrea, Savidge, Tor, Piskorz, María Marta

المساهمون: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases

المصدر: Journal of Functional Foods ; volume 99, page 105356 ; ISSN 1756-4646

مصطلحات موضوعية: Nutrition and Dietetics, Medicine (miscellaneous), Food Science

الإتاحة: https://doi.org/10.1016/j.jff.2022.105356Test
https://api.elsevier.com/content/article/PII:S1756464622004261?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1756464622004261?httpAccept=text/plainTest

المؤلفون: Molino, Silvia, Pisarevsky, Andrea, Mingorance, Fabiana Lopez, Vega, Patricia, Stefanolo, Juan Pablo, Repetti, Julieta, Ludueña, Guillermina, Pepa, Pablo, Olmos, Juan Ignacio, Fermepin, Marcelo Rodriguez, Uehara, Tatiana, Villapol, Sonia, Savidge, Tor, Treangen, Todd, Viciani, Elisa, Castagnetti, Andrea, Piskorz, Maria Marta

مصطلحات موضوعية: COVID-19, Chestnut tannins, Quebracho tannins, Randomized controlled trial, gut microbiota, inflammation, protocol, Adolescent, Adult, Argentina, Dietary Supplements, Female, Humans, Lactation, Plant Extracts, Pregnancy, Prospective Studies, RNA, Viral, Randomized Controlled Trials as Topic, SARS-CoV-2, Tannins, Treatment Outcome

الوصف: This research aims to study the efficacy of tannins co-supplementation on disease duration, severity and clinical symptoms, microbiota composition and inflammatory mediators in SARS-CoV2 patients. This is a prospective, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy of the administration of the dietary supplement ARBOX, a molecular blend of quebracho and chestnut tannins extract and Vit B12, in patients affected by COVID-19. 18 years of age or older, admitted to Hospital de Clinicas Jose de San Martin, Buenos Aires University (Argentina), meeting the definition of "COVID-19 confirmed case" ( https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion-de-casoTest ). Inclusion Criteria Participants are eligible to be included in the study if the following criteria apply: 1. Any gender 2. ≥18 years old 3. Informed consent for participation in the study 4. Virological diagnosis of SARS-CoV-2 infection (real-time PCR) Exclusion Criteria Participants are excluded from the study if any of the following criteria apply: 1. Pregnant and lactating patients 2. Patients who cannot take oral therapy (with severe cognitive decline, assisted ventilation, or impaired consciousness) 3. Hypersensitivity to polyphenols 4. Patients already in ICU or requiring mechanical ventilation 5. Patients already enrolled in other clinical trials 6. Decline of consent INTERVENTION AND COMPARATOR: Experimental: TREATED ARM Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day. Placebo Comparator: CONTROL ARM Participants will receive placebo supply for 14 days. The placebo will be administered with the identical dose as described for the test product. All trial participants will receive standard therapy, which includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas ...

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/17648Test; PMC8080998; https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/s13063-021-05281-xTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080998/pdfTest

الإتاحة: https://doi.org/10.1186/s13063-021-05281-xTest
http://hdl.handle.net/10668/17648Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080998/pdfTest

المؤلفون: Pisarevsky, Ana A., Mingorance, Fabiana Lopez, Vega, Patrica, Stefanolo, Juan P., Repetti, Julieta A., Ludueña, Guillermina, Pepa, Pablo D., Olmos, Juan I., Fermepin, Marcelo Rodríguez, Molino, Silvia, Uehara, Tatiana, Viciani, Elisa, Villapol, Sonia, Castagnetti, Andrea, Savidge, Tor C., Treangen, Todd J., Piskorz, Maria

المصدر: Gastroenterology ; volume 160, issue 6, page S-371 ; ISSN 0016-5085

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/s0016-5085Test(21)01599-7
https://api.elsevier.com/content/article/PII:S0016508521015997?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0016508521015997?httpAccept=text/plainTest

المؤلفون: Pepa, Pablo, Uehara, Tatiana, Wonaga, Andrés, Redondo, Agustina, Avagnina, Alejandra, Mazzocchi, Octavio, Antelo, Pablo, Waldbaum, Carlos, Sorda, Juan

المصدر: Medicina (Buenos Aires), Volume: 81, Issue: 3, Pages: 470-473, Published: JUN 2021

مصطلحات موضوعية: Menetrier’s disease, Gastropatía hipertrófica, Cetuximab, Hypertrophic gastropathy, enfermedad de Menetrier

الوصف: We present a rare case of hypertrophic gastropathy associated with protein loss. A 35-year-old man was hospitalized for bowel habit changes, abdominal pain, generalized edema and symptomatic anemia. Pertinent laboratory findings included iron deficiency anemia (Hb 6.7g/dl, ferritin 5 ng/ml) and marked hypoalbuminemia (albumin 2.5 g/dl). Endoscopic biopsy samples of giant gastric folds observed along the greater gastric curvature revealed foveolar hyperplasia and significant parietal cell loss. Endoscopic ultrasonography showed gastric parietal thickening with preserved architecture and normal gastric wall layers. Menetrier disease was diagnosed and the patient treated with cetuximab, a monoclonal antibody that inhibits ligand binding of trans forming growth factor alpha (TGFa), preventing gastric mucosa cell proliferation. After twelve months of treatment, the patient referred symptoms improvement, and gastric biopsy levels of the proliferation marker protein Ki-67 had decreased. Resumen Presentamos un caso infrecuente de gastropatía hipertrófica asociada a pérdida de proteínas. Un hombre de 35 años fue hos pitalizado por cambios en los hábitos intestinales, dolor abdominal, edema generalizado y anemia sintomática. Los hallazgos de laboratorio pertinentes incluyeron anemia ferropénica (Hb 6.7 g/dl, ferritina 5 ng/ml) e hipoal buminemia marcada (albúmina 2.5 g/dl). Las muestras de biopsia endoscópica de pliegues gástricos gigantes observados a lo largo de la curvatura mayor gástrica revelaron hiperplasia foveolar y pérdida significativa de células parietales. La ecografía endoscópica mostró engrosamiento parietal gástrico con arquitectura conservada y capas de pared gástrica normales. Se diagnosticó enfermedad de Menetrier y se trató al paciente con cetuximab, un anticuerpo monoclonal que inhibe la unión del ligando del factor de crecimiento transformante alfa (TGFa), evitando la proliferación de células de la mucosa gástrica. Después de doce meses de tratamiento, el paciente refirió mejoría de los síntomas y los niveles de la proteína marcadora de proliferación Ki-67 en biopsia gástrica habían disminuido.

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od_______617::534a9bf624cea16d8448fcfc6d0397bfTest
http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802021000300470&lng=en&tlng=enTest

العنوان البديل: Enfermedad de Menetrier. Un desafío diagnóstico y terapéutico. (Spanish)

المؤلفون: PEPA, PABLO, UEHARA, TATIANA, WONAGA, ANDRÉS, REDONDO, AGUSTINA, AVAGNINA, ALEJANDRA, MAZZOCCHI, OCTAVIO, ANTELO, PABLO, WALDBAUM, CARLOS, SORDA, JUAN

المصدر: Medicina (Buenos Aires); may/jun2021, Vol. 81 Issue 3, p470-473, 4p

الملخص (بالإنجليزية): We present a rare case of hypertrophic gastropathy associated with protein loss. A 35-year-old man was hospitalized for bowel habit changes, abdominal pain, generalized edema and symptomatic anemia. Pertinent laboratory findings included iron deficiency anemia (Hb 6.7g/dl, ferritin 5 ng/ml) and marked hypoalbuminemia (albumin 2.5 g/dl). Endoscopic biopsy samples of giant gastric folds observed along the greater gastric curvature revealed foveolar hyperplasia and significant parietal cell loss. Endoscopic ultrasonography showed gastric parietal thickening with preserved architecture and normal gastric wall layers. Menetrier disease was diagnosed and the patient treated with cetuximab, a monoclonal antibody that inhibits ligand binding of transforming growth factor alpha (TGFa), preventing gastric mucosa cell proliferation. After twelve months of treatment, the patient referred symptoms improvement, and gastric biopsy levels of the proliferation marker protein Ki-67 had decreased. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Presentamos un caso infrecuente de gastropatía hipertrófica asociada a pérdida de proteínas. Un hombre de 35 años fue hospitalizado por cambios en los hábitos intestinales, dolor abdominal, edema generalizado y anemia sintomática. Los hallazgos de laboratorio pertinentes incluyeron anemia ferropénica (Hb 6.7 g/dl, ferritina 5 ng/ml) e hipoalbuminemia marcada (albúmina 2.5 g/dl). Las muestras de biopsia endoscópica de pliegues gástricos gigantes observados a lo largo de la curvatura mayor gástrica revelaron hiperplasia foveolar y pérdida significativa de células parietales. La ecografía endoscópica mostró engrosamiento parietal gástrico con arquitectura conservada y capas de pared gástrica normales. Se diagnosticó enfermedad de Menetrier y se trató al paciente con cetuximab, un anticuerpo monoclonal que inhibe la unión del ligando del factor de crecimiento transformante alfa (TGFa), evitando la proliferación de células de la mucosa gástrica. Después de doce meses de tratamiento, el paciente refirió mejoría de los síntomas y los niveles de la proteína marcadora de proliferación Ki-67 en biopsia gástrica habían disminuido. [ABSTRACT FROM AUTHOR]

: Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)